Rabbit Recombinant Monoclonal EEF2/Elongation factor 2 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation (PubMed:26593721). During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively (PubMed:26593721). Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome (PubMed:26593721).
EF2, EEF2, Elongation factor 2, EF-2
Rabbit Recombinant Monoclonal EEF2/Elongation factor 2 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
EEF2 or elongation factor 2 is an important protein in the process of translation during protein synthesis. It is also known by the names EF-2 and EF2. This protein facilitates the translocation step where it moves tRNA and mRNA from the A-site to the P-site on the ribosome. EEF2 has a molecular weight of approximately 95 kDa. The protein is ubiquitously expressed in various tissues and cells due to its fundamental role in protein synthesis making it essential for cellular activities.
EEF2 functions as part of a larger ribosomal complex. It has an important role in ensuring the accuracy and efficiency of elongation during the translation process. This process is energy-dependent with EEF2 requiring GTP to catalyze the movement along the mRNA strand. The protein must undergo reversible phosphorylation which directly affects its activity. This post-translational modification of EEF2 is a significant modulation point influencing the rate of protein synthesis.
EEF2 plays an integral role in the mTOR signaling pathway and the insulin signaling pathway. In the mTOR pathway EEF2 activity is regulated to control protein translation based on cellular energy status and nutrient availability. This pathway is important for cell growth and proliferation. EEF2 interacts with other proteins such as factor 2 and eEF2kinase which phosphorylates the protein thereby inhibiting its activity. In the insulin signaling pathway similar regulatory mechanisms impact EEF2’s role in translation.
EEF2 connects to cancer and neurodegenerative diseases. In cancer aberrant regulation of EEF2 can lead to uncontrolled protein synthesis promoting cell proliferation and tumor growth. Its interaction with mTOR and other signaling proteins like ribosomal proteins plays a role in this dysregulation. In neurodegenerative conditions such as Alzheimer’s disease impaired EEF2 activity results in decreased synaptic protein synthesis affecting neuronal function. Understanding EEF2’s regulation and dysregulation provides insight into its involvement in these diseases offering potential for therapeutic intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com